年龄对异环磷酰胺药代动力学的影响。
The effect of age on the pharmacokinetics of ifosfamide.
作者信息
Lind M J, Margison J M, Cerny T, Thatcher N, Wilkinson P M
机构信息
Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester.
出版信息
Br J Clin Pharmacol. 1990 Jul;30(1):140-3. doi: 10.1111/j.1365-2125.1990.tb03754.x.
Abstract
The effect of age on the pharmacokinetics of ifosfamide was studied in 20 patients with advanced non small cell lung cancer. A positive correlation was found between the elimination half-life of ifosfamide and age (r = 0.48, 0.05 less than P less than 0.01). This was due to an increase in volume of distribution with age (r = 0.66, 0.001 less than P less than 0.01). Total plasma clearance, renal clearance and non renal clearance did not change with age. Age did not affect the autoinduction of ifosfamide metabolism. Further studies are needed to demonstrate any adverse effects of ifosfamide in the elderly.
摘要
在20例晚期非小细胞肺癌患者中研究了年龄对异环磷酰胺药代动力学的影响。发现异环磷酰胺的消除半衰期与年龄呈正相关（r = 0.48，0.05 ＜ P ＜ 0.01）。这是由于分布容积随年龄增加（r = 0.66，0.001 ＜ P ＜ 0.01）。总血浆清除率、肾清除率和非肾清除率不随年龄变化。年龄不影响异环磷酰胺代谢的自身诱导作用。需要进一步研究以证实异环磷酰胺在老年人中的任何不良反应。
相似文献
1
The effect of age on the pharmacokinetics of ifosfamide.年龄对异环磷酰胺药代动力学的影响。
Br J Clin Pharmacol. 1990 Jul;30(1):140-3. doi: 10.1111/j.1365-2125.1990.tb03754.x.
2
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.由于药物分布改变，肥胖患者异环磷酰胺消除半衰期延长。
Cancer Chemother Pharmacol. 1989;25(2):139-42. doi: 10.1007/BF00692355.
3
Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.在小细胞肺癌患者中单次静脉输注消旋体1小时后异环磷酰胺及其对映体的药代动力学。
Br J Clin Pharmacol. 1995 Apr;39(4):452-5. doi: 10.1111/j.1365-2125.1995.tb04477.x.
4
Ifosfamide enantiomers: pharmacokinetics in children.异环磷酰胺对映体：儿童药代动力学
Cancer Chemother Pharmacol. 1994;34(5):447-9. doi: 10.1007/BF00685573.
5
A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles.连续治疗周期中5日分次给药异环磷酰胺的药代动力学研究。
Br J Clin Pharmacol. 1996 Aug;42(2):179-86. doi: 10.1046/j.1365-2125.1996.03956.x.
6
Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.
Cancer Chemother Pharmacol. 2001 Jul;48(1):53-61. doi: 10.1007/s002800100277.
7
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.使用NONMEM通过群体药代动力学方法评估异环磷酰胺代谢的自身诱导作用。
Br J Clin Pharmacol. 2000 Jun;49(6):555-61. doi: 10.1046/j.1365-2125.2000.00217.x.
8
Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Cancer Res. 1993 Aug 15;53(16):3758-64.
9
Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients.口服(-)-(S)-溴磷酰胺在肺癌患者中的药代动力学及毒性研究
Arzneimittelforschung. 2001;51(7):600-3. doi: 10.1055/s-0031-1300086.
10
Ifosfamide clinical pharmacokinetics.异环磷酰胺的临床药代动力学。
Clin Pharmacokinet. 1994 Jun;26(6):439-56. doi: 10.2165/00003088-199426060-00003.
引用本文的文献
1
The aging kidney: a review--part II.衰老的肾脏：综述——第二部分。
Int Urol Nephrol. 2005;37(2):419-32. doi: 10.1007/s11255-004-0874-5.
2
The influence of age and sex on the clearance of cytochrome P450 3A substrates.年龄和性别对细胞色素P450 3A底物清除率的影响。
Clin Pharmacokinet. 2005;44(1):33-60. doi: 10.2165/00003088-200544010-00002.
3
Pharmacology of anticancer drugs in the elderly population.老年人群中抗癌药物的药理学
Clin Pharmacokinet. 2003;42(14):1213-42. doi: 10.2165/00003088-200342140-00003.
4
All half-lives are wrong, but some half-lives are useful.所有半衰期都是不准确的，但有些半衰期是有用的。
Clin Pharmacokinet. 2001;40(4):237-44. doi: 10.2165/00003088-200140040-00001.
5
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.异环磷酰胺及其代谢产物的临床药代动力学和药效学
Clin Pharmacokinet. 2001 Jan;40(1):41-62. doi: 10.2165/00003088-200140010-00004.
6
Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.
Cancer Chemother Pharmacol. 1996;37(5):451-6. doi: 10.1007/s002800050411.
7
Ifosfamide clinical pharmacokinetics.异环磷酰胺的临床药代动力学。
Clin Pharmacokinet. 1994 Jun;26(6):439-56. doi: 10.2165/00003088-199426060-00003.
8
Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.在小细胞肺癌患者中单次静脉输注消旋体1小时后异环磷酰胺及其对映体的药代动力学。
Br J Clin Pharmacol. 1995 Apr;39(4):452-5. doi: 10.1111/j.1365-2125.1995.tb04477.x.
9
Ifosfamide pharmacokinetics.
Invest New Drugs. 1991 Nov;9(4):305-11. doi: 10.1007/BF00183570.
10
Dosing and side-effects of ifosfamide plus mesna.异环磷酰胺加美司钠的剂量及副作用
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S164-86. doi: 10.1007/BF01613224.
本文引用的文献
1
[ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO].[关于环磷酰胺在体内和体外的活化作用]
Arzneimittelforschung. 1963 Dec;13:1021-31.
2
Anatomy of body water and electrolytes.人体水和电解质的解剖学
Am J Med. 1959 Aug;27:256-77. doi: 10.1016/0002-9343(59)90346-8.
3
Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.通过改良荧光测定法对活化异环磷酰胺和环磷酰胺人体药代动力学的比较研究。
J Cancer Res Clin Oncol. 1981;100(1):95-104. doi: 10.1007/BF00405906.
4
The oxazaphosphorines.
Cancer Treat Rev. 1983 Sep;10 Suppl A:3-15. doi: 10.1016/s0305-7372(83)80002-4.
5
Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).单剂量推注、分次注射或持续输注氮杂磷类药物（环磷酰胺、异环磷酰胺、Asta Z 7557）的治疗效果。
Cancer. 1984 Sep 15;54(6 Suppl):1193-203. doi: 10.1002/1097-0142(19840915)54:1+<1193::aid-cncr2820541317>3.0.co;2-z.
6
7
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.2-巯基乙烷磺酸钠（美司钠）预防晚期癌症患者异环磷酰胺诱导的尿路上皮毒性
Lancet. 1980 Sep 27;2(8196):657-9. doi: 10.1016/s0140-6736(80)92703-8.
8
Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.一些关于环磷酰胺和异环磷酰胺微粒体代谢过程中形成的活性中间体的研究。
Biochem Pharmacol. 1974 Jan 1;23(1):115-29. doi: 10.1016/0006-2952(74)90318-9.
9
Evaluation of cis-diamminedichloroplatinum(II) combined with metoclopramide or sodium thiosulfate on L1210 leukemia in vitro and in vivo.顺二氯二氨铂（II）联合胃复安或硫代硫酸钠对L1210白血病的体内外评价
Cancer Chemother Pharmacol. 1986;18(1):1-4. doi: 10.1007/BF00253053.
10
A simple quantitative HPLC assay for ifosfamide in biological fluids.一种用于生物流体中异环磷酰胺的简单定量高效液相色谱分析法。
Biomed Chromatogr. 1986 Jun;1(3):101-3. doi: 10.1002/bmc.1130010303.
Zotero 插件